BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia

References

• Butturini A, Bortin MM, Gale RP. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2(3):233–42; PMID:3332173
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96(2):384–92; PMID:10887096; http://dx.doi.org.gate2.inist.fr/
   PubMed Web of Science ®Google Scholar
• Castella B, Vitale C, Coscia M, Massaia M. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci CMLS 2011; 68(14):2419–32; PMID:21584812; http://dx.doi.org/10.1007/s00018-011-0704-8
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 2004; 173(11):6767–76; PMID:15557170; http://dx.doi.org/10.4049/jimmunol.173.11.6767
   PubMed Web of Science ®Google Scholar
• Norell H, Moretta A, Silva-Santos B, Moretta L. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias. J Leukoc Biol 2013; 94(6):1123–39; PMID:24108703; http://dx.doi.org/10.1189/jlb.0613312
   PubMed Web of Science ®Google Scholar
• Locatelli F, Merli P, Rutella S. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol 2013; 94(6):1141–57; PMID:24096380; http://dx.doi.org/10.1189/jlb.0613343
   PubMed Web of Science ®Google Scholar
• Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39(12):751–7; PMID:17450185; http://dx.doi.org/10.1038/sj.bmt.1705650
   PubMed Web of Science ®Google Scholar
• Meeh PF, King M, O'Brien RL, Muga S, Buckhalts P, Neuberg R, Lamb LS, Jr. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother 2006; 55(9):1072–80; PMID:16328383; http://dx.doi.org/10.1007/s00262-005-0094-6
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197(2):163–8; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500
   PubMed Web of Science ®Google Scholar
• Li J, Herold MJ, Kimmel B, Müller I, Rincon-Orozco B, Kunzmann V, Herrmann T. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells. J Immunol 2009; 182(12):8118–24; PMID:19494338; http://dx.doi.org/10.4049/jimmunol.0900101
   PubMed Web of Science ®Google Scholar
• Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, Touraine JL, Clézardin P. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011; 71(13):4562–72; PMID:21646473; http://dx.doi.org/10.1158/0008-5472.CAN-10-3862
   PubMed Web of Science ®Google Scholar
• Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, Charbonnier A, Collette Y, Vey N, Olive D. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 2012; 188(9):4701–8; PMID:22467661; http://dx.doi.org/10.4049/jimmunol.1103710
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, Becker J, Schmidt-Wolf IG, Einsele H, Wilhelm M. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 2012; 35(2):205–13; PMID:22306909; http://dx.doi.org/10.1097/CJI.0b013e318245bb1e
   PubMed Web of Science ®Google Scholar
• Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C et al. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood 2012; 120(16):3271–9; PMID:22932792; http://dx.doi.org/10.1182/blood-2012-03-417519
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, Kunzmann V. Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells. J Transl Med 2014; 12:45; PMID:24528541; http://dx.doi.org/10.1186/1479-5876-12-45
   PubMed Web of Science ®Google Scholar
• Gundermann S, Klinker E, Kimmel B, Flierl U, Wilhelm M, Einsele H, Kunzmann V. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells. J Immunother 2014; 37(6):321–30; PMID:24911793; http://dx.doi.org/10.1097/CJI.0000000000000043
   PubMed Web of Science ®Google Scholar
• Compte E, Pontarotti P, Collette Y, Lopez M, Olive D. Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J Immunol 2004; 34(8):2089–99; PMID:15259006; http://dx.doi.org/10.1002/eji.200425227
   PubMed Web of Science ®Google Scholar
• Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, Madore J, Delvoye N, Mes-Masson AM, Provencher DM et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PloS One 2012; 7(6):e38541; PMID:22685580; http://dx.doi.org/10.1371/journal.pone.0038541
   PubMed Web of Science ®Google Scholar
• Rhodes DA, Chen HC, Price AJ, Keeble AH, Davey MS, James LC, Eberl M, Trowsdale J. Activation of Human γδ T Cells by Cytosolic Interactions of BTN3A1 with Soluble Phosphoantigens and the Cytoskeletal Adaptor Periplakin. J Immunol 2015; 194(5):2390–8; PMID:25637025; http://dx.doi.org/10.4049/jimmunol.1401064
   PubMed Web of Science ®Google Scholar
• Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, Li J, Kuball J, Adams EJ, Netzer S et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 2012; 120(11):2269–79; PMID:22767497; http://dx.doi.org/10.1182/blood-2012-05-430470
   PubMed Web of Science ®Google Scholar
• Wang H, Henry O, Distefano MD, Wang YC, Räikkönen J, Mönkkönen J, Tanaka Y, Morita CT. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol 2013; 191(3):1029–42; PMID:23833237; http://dx.doi.org/10.4049/jimmunol.1300658
   PubMed Web of Science ®Google Scholar
• Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, Breathnach R, Bonneville M, Scotet E, Adams EJ. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014; 40(4):490–500; PMID:24703779; http://dx.doi.org/10.1016/j.immuni.2014.03.003
   PubMed Web of Science ®Google Scholar
• Wang H, Morita CT. Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells. J Immunol 2015; 195(10):4583–94; PMID:26475929; http://dx.doi.org/10.4049/jimmunol.1500314
   PubMed Web of Science ®Google Scholar
• Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, Scotet E, Bonneville M, Adams EJ. The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem 2012; 287(39):32780–90; PMID:22846996; http://dx.doi.org/10.1074/jbc.M112.384354
   PubMed Web of Science ®Google Scholar
• Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8(9):2736–45; PMID:19723883; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275
   PubMed Web of Science ®Google Scholar
• Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, Plet A, Jacques Y. Soluble interleukin-15 receptor α (IL-15R α)-sushi as a selective and potent agonist of IL-15 action through IL-15R β/gamma. Hyperagonist IL-15 x IL-15R α fusion proteins. J Biol Chem 2006; 281(3):1612–9; PMID:16284400; http://dx.doi.org/10.1074/jbc.M508624200
   PubMed Web of Science ®Google Scholar
• Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, Bagg A, Choi JK, Biegel JA, Danet-Desnoyers G et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009; 23(11):2109–17; PMID:19626050; http://dx.doi.org/10.1038/leu.2009.143
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102(1):200–6; PMID:12623838; http://dx.doi.org/10.1182/blood-2002-12-3665
   PubMed Web of Science ®Google Scholar
• Idrees ASM, Sugie T, Inoue C, Murata-Hirai K, Okamura H, Morita CT, Minato N, Toi M, Tanaka Y. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Sci 2013; 104(5):536–42; PMID:23387443; http://dx.doi.org/10.1111/cas.12124
   PubMed Web of Science ®Google Scholar
• Riaño F, Karunakaran MM, Starick L, Li J, Scholz CJ, Kunzmann V, Olive D, Amslinger S, Herrmann T. Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6. Eur J Immunol 2014; 44(9):2571–6; http://dx.doi.org/10.1002/eji.201444712
   PubMed Web of Science ®Google Scholar
• Messal N, Mamessier E, Sylvain A, Celis-Gutierrez J, Thibult ML, Chetaille B, Firaguay G, Pastor S, Guillaume Y, Wang Q et al. Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. Eur J Immunol 2011; 41(12):3443–54; PMID:21918970; http://dx.doi.org/10.1002/eji.201141404
   PubMed Web of Science ®Google Scholar
• Gertner J, Wiedemann A, Poupot M, Fournié J-J. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett 2007; 110(1):42–53; PMID:17451812; http://dx.doi.org/10.1016/j.imlet.2007.03.002
   PubMed Web of Science ®Google Scholar
• Gertner-Dardenne J, Poupot M, Gray B, Fournié JJ. Lipophilic fluorochrome trackers of membrane transfers between immune cells. Immunol Invest 2007; 36(5–6):665–85; PMID:18161524; http://dx.doi.org/10.1080/08820130701674646
   PubMedGoogle Scholar